Impact of tumor localization on antitumor immunity with conditionally activated CTLA-4 blockade

Impact of tumor localization on antitumor immunity with conditionally activated CTLA-4 blockade

Background Immune checkpoint blockade (ICB) can induce antitumor efficacy but also induces immune-related adverse events. Systemically administered ICB can activate immune cells throughout the host. Conditionally active ICB with proteolytically cleaved masking domains can potentially reduce the adve...

Full description

Saved in:

Bibliographic Details
Main Authors:	Lawrence Fong, Miho Tanaka, Jacob V Gorman, Marcel Arias-Badia, Chien-Chun Steven Pai, Yee May Lwin, PeiXi Chen, Aahir Srinath, Emily Musser, Andrew Goodearl, Wendy Ritacco
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2025-04-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/13/4/e010566.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Inosine shapes PD-1 blockade responses and synergizes with dual PD-1/CTLA-4 immunotherapy to enhance antitumor immunity
by: Yoichiro Narikawa, et al.
Published: (2025-08-01)

Impact of steroid dose and timing on efficacy of combination PD-1/CTLA-4 blockade
by: Nina B. Curkovic, et al.
Published: (2025-12-01)

Personalized neoantigen hydrogel vaccine combined with PD-1 and CTLA-4 double blockade elicits antitumor response in liver metastases by activating intratumoral CD8+CD69+ T cells
by: Huan Yang, et al.
Published: (2024-12-01)

Prophylactic IL-23 blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy
by: Ting Chen, et al.
Published: (2024-07-01)

Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy: The Underlying Mechanisms and Clinical Management
by: Ahmad Tarhini
Published: (2013-01-01)

CTLA-4 and PD-1 combined blockade therapy for malignant melanoma brain metastases: mechanisms, challenges, and prospects
by: Jia-Wen Wang, et al.
Published: (2025-07-01)

Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade.
by: Nobuhiro Nakamoto, et al.
Published: (2009-02-01)

VEGF blockade enhances the antitumor effect of BRAFV600E inhibition
by: Valentina Comunanza, et al.
Published: (2016-12-01)

CTLA-4 blockade and interferon-α induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma.
by: Arjun Khunger, et al.
Published: (2021-01-01)

Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy
by: Xia Liu, et al.
Published: (2022-10-01)

CD39+ conventional CD4+ T cells with exhaustion traits and cytotoxic potential infiltrate tumors and expand upon CTLA-4 blockade
by: Sabrina N. Bossio, et al.
Published: (2023-12-01)

Combined PD-1 and CTLA-4 Blockade Increases the Risks of Multiple Pituitary Hormone Deficiency and Isolated Adrenocorticotropic Deficiency: A Prospective Study
by: Shintaro Iwama, et al.
Published: (2025-06-01)

First-in-human evaluation of memory-like NK cells with an IL-15 super-agonist and CTLA-4 blockade in advanced head and neck cancer
by: Roman M. Shapiro, et al.
Published: (2025-02-01)

PD-1/CTLA-4 Blockade Inhibits Epstein-Barr Virus-Induced Lymphoma Growth in a Cord Blood Humanized-Mouse Model.
by: Shi-Dong Ma, et al.
Published: (2016-05-01)

LILRB2 blockade facilitates macrophage repolarization and enhances T cell-mediated antitumor immunity
by: D Gareth Rees, et al.
Published: (2025-04-01)

Long-Term Response to PD-1 and CTLA-4 Blockade in an SCLC Patient with Negative PD-L1 Expression on Biopsy: A Case Report
by: Marco Cefalì, et al.
Published: (2023-03-01)

PD-1 blockade employed at the time CD8+ T cells are activated enhances their antitumor efficacy
by: Douglas G McNeel, et al.
Published: (2025-05-01)

Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort
by: Howard Streicher, et al.
Published: (2024-07-01)

CD155 blockade enhances allogeneic natural killer cell-mediated antitumor response against osteosarcoma
by: Lei Shi, et al.
Published: (2025-04-01)

Cryoablation combined with dual immune checkpoint blockade enhances antitumor efficacy in hepatocellular carcinoma model mice
by: Jun Gu, et al.
Published: (2024-12-01)

Methionine Metabolism Dictates PCSK9 Expression and Antitumor Potency of PD‐1 Blockade in MSS Colorectal Cancer
by: Qi‐Long Wang, et al.
Published: (2025-05-01)

TNFR2 blockade promotes antitumoral immune response in PDAC by targeting activated Treg and reducing T cell exhaustion
by: Eliane Piaggio, et al.
Published: (2024-11-01)

Phase II basket trial of Dual Anti-CTLA-4 and anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: pancreatic neuroendocrine neoplasm (PNEN) cohort
by: Ignacio I Wistuba, et al.
Published: (2025-06-01)

Small extracellular vesicle miRNAs as biomarkers for predicting antitumor efficacy in lung adenocarcinoma treated with chemotherapy and checkpoint blockade
by: Si Sun, et al.
Published: (2025-03-01)

Comparison of the intracellular trafficking itinerary of ctla-4 orthologues.
by: Satdip Kaur, et al.
Published: (2013-01-01)

Second-line treatment of PD-1 and CTLA-4 blockade combined with liposomal irinotecan plus leucovorin and fluorouracil for advanced cholangiocarcinoma: study protocol of a single-arm, prospective phase II trial
by: Heqi Yang, et al.
Published: (2024-10-01)

Targeting KIF18A triggers antitumor immunity and enhances efficiency of PD-1 blockade in colorectal cancer with chromosomal instability phenotype
by: Gang Liu, et al.
Published: (2025-04-01)

Inhibition of integrin αvβ6 sparks T-cell antitumor response and enhances immune checkpoint blockade therapy in colorectal cancer
by: Gerhard Rogler, et al.
Published: (2022-02-01)

Engineered ipilimumab variants that bind human and mouse CTLA-4
by: Brett Robison, et al.
Published: (2025-12-01)

CTLA-4 expression on tregs is needed for suppression of autoimmune uveitis
by: Minjun Ahn, et al.
Published: (2025-05-01)

Corrigendum to “Second-line treatment of PD-1 and CTLA-4 blockade combined with liposomal irinotecan plus leucovorin and fluorouracil for advanced cholangiocarcinoma: study protocol of a single-arm, prospective phase II trial”
Published: (2025-07-01)

Alum-anchored IL-12 combined with cytotoxic chemotherapy and immune checkpoint blockade enhanced antitumor immune responses in head and neck cancer models
by: James W Hodge, et al.
Published: (2024-10-01)

GSH-responsive polymeric micelles-based augmented photoimmunotherapy synergized with PD-1 blockade for eliciting robust antitumor immunity against colon tumor
by: Chenlu Huang, et al.
Published: (2024-09-01)

Correlation of TSHR and CTLA-4 Single Nucleotide Polymorphisms with Graves Disease
by: Weihua Sun, et al.
Published: (2019-01-01)

The effect of HLA genotype on disease onset and severity in CTLA-4 insufficiency
by: Sara Posadas-Cantera, et al.
Published: (2025-01-01)

Highly selective HPK1 inhibitor NDI-101150 mediates immune cell activation and robust antitumor responses, distinct from immune checkpoint blockade
by: Samantha Carreiro, et al.
Published: (2025-07-01)

Unconquered by the Blockade
by: E. M. Proshina
Published: (2018-06-01)

A phase II basket trial of dual anti‐CTLA‐4 and anti‐PD‐1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort
by: Young Kwang Chae, et al.
Published: (2025-08-01)

Prolonged Disease Course of COVID-19 in a Patient with CTLA-4 Haploinsufficiency
by: T. W. Hoffman, et al.
Published: (2023-01-01)

Microwave Ablation Combined with Flt3L Provokes Tumor‐Specific Memory CD8+ T Cells‐Mediated Antitumor Immunity in Response to PD‐1 Blockade
by: Meixiang Wang, et al.
Published: (2025-01-01)